15.25
+13.81%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MegaPro Biomedical Co
Its shares trade on Taipei Exchange under the ticker 6827.TWO. It has been listed since 19 October 2021. In the fiscal year to 31 December 2024, it reported revenue of TWD 14,000 and a net loss of TWD 164.0m. At that date it held total assets of TWD 224.3m and shareholders' equity of TWD 204.4m.
MegaPro Biomedical Co., Ltd. engages in the development of drug ingredients related to nanoparticles and nanocell technology platforms. The company is headquartered in Zhubei, Hsinchu. The company went IPO on 2021-10-19. The firm mainly has two nanotechnology platforms including nanoparticle and nanocell. The firm's products include MPB-1514, MPB-1523, MPB-1734 and MPB-2043. MPB-1514 is mainly used to treat patients with anemia due to chronic kidney disease by intravenous injection. MPB-1523 is mainly used intravenously to diagnose patients with hepatocellular carcinoma. MPB-1734 is mainly used to treat patients with solid tumors by intravenous injection. MPB-2043 is mainly used intravenously to diagnose patients with metastases in the peripheral lymph nodes of the cancerous site.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Oct 2021
- Employees
- 20
- Website
- megaprobio.com ↗
Leadership
Pay as last reported
- Mr. Wei-Feng ChiangChairman of the Board, Chief Strategy Officer, since 2021
- Ms. Jassy WangChief Executive Officer, Director, since 2015
- Mr. Yuan-Hon HsuGeneral Manager, Director, since 2021
- Mr. Mark ChiuDeputy General Manager-Operating Center, Head of Finance & Accounting
- Zhilong ChenDirector
- Mr. Zhiyong WuDirector
- Mr. Tsu-Sheng FuIndependent Director
- Mr. Qichang HongIndependent Director
- Mr. Chaotong WuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MegaPro Biomedical operates two distinct nanotechnology platforms.
- The company has developed four specific drug products for clinical use.
- IPO occurred on 2021-10-19 to support its operations.
Weaknesses
- The firm employs only twenty staff members globally.
- Headquarters are located in Zhubei, Hsinchu, which may limit talent pools.
- Reliance on intravenous injection methods restricts administration routes.
Opportunities
- MPB-1514 targets the significant market of chronic kidney disease anemia.
- MPB-1734 addresses the broad therapeutic area of solid tumors.
- MPB-1523 and MPB-2043 offer diagnostic solutions for liver cancer and metastases.
Threats
- Small workforce size may hinder rapid scaling of research efforts.
- Regulatory hurdles exist for new nanoparticle drug ingredients.
- Competition in the biotechnology sector poses risks to market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.